Vilon

Vilon is a synthetic dipeptide (Lys-Glu or KE) that was identified as one of the key immunomodulatory active components within Thymalin, a pharmaceutical containing natural thymic peptide extracts. While Thymalin contains a complex mixture of thymic peptides, Vilon is the purified synthetic version of just the KE dipeptide — offering the targeted immunomodulatory and geroprotective effects of this specific component. Studies have confirmed that the KE dipeptide drives much of Thymalin's T-cell activation, cytokine regulation, and anti-inflammatory activity.

In direct comparisons, Vilon (KE) produces the most potent thymocyte proliferative effect among tested Khavinson bioregulators — superior to both Epithalon (AEDG, pineal bioregulator) and Cortagen (AEDP, brain bioregulator). Vilon also shows more pronounced activation of the sphingomyelin signal transduction pathway. While Epithalon specializes in pineal/melatonin function and Cortagen in neuroprotection, Vilon is the most potent immune-specific bioregulator in the Khavinson family.

SIRT1 (sirtuin-1) is a NAD+-dependent deacetylase considered a master longevity regulator — it promotes DNA repair, telomere maintenance, oxidative stress resistance, and metabolic efficiency. PARP1/PARP2 compete with SIRT1 for NAD+ and are overexpressed during aging, depleting the NAD+ pool available for SIRT1 activity. Vilon rebalances this axis by upregulating SIRT1 (6-8.2 fold) while downregulating PARP1/PARP2 (2.1-5.3 fold), restoring the NAD+ allocation toward longevity pathways. This dual mechanism is considered one of the most direct interventions against fundamental aging mechanisms.

Published clinical evidence supports Vilon as an adjunctive therapy for cancer patients. In a study of elderly Stage III colorectal cancer patients, adding Vilon to standard radio/chemotherapy improved 2-year survival, reduced post-operative complications, prevented tumor recurrence and dissemination, and improved quality of life. In animal models, Vilon reduced urinary bladder tumor incidence from 75.5% to 56% with a 2-fold decrease in pre-neoplastic lesions. These oncostatic effects are attributed to activation of heterochromatin-silenced genes and inhibition of reactive oxygen species formation.

Vilon (Lys-Glu) is one of the smallest bioactive peptides known, and its efficacy has been extensively documented across dozens of peer-reviewed studies. The KE dipeptide achieves biological activity through direct interaction with specific DNA sequences (GCGG in B-form DNA, GGGC in nucleosomal DNA) in gene promoter regions. This ultra-short structure actually provides advantages: efficient cellular uptake via peptide transporters, direct nuclear penetration without carrier proteins, and rapid tissue distribution. The specificity comes not from the peptide's size but from its precise fit into DNA promoter sequences of target genes.

Unlike conventional immunostimulants that broadly activate immune responses, Vilon works through epigenetic gene regulation to restore proper immune function. It simultaneously enhances adaptive immunity (T-cell maturation via CD5/CD4/CD8 pathway activation) while reducing pathological inflammation (IL-1β, IL-6, TNF-α reduction). This dual immunomodulatory action — boosting beneficial immune responses while suppressing harmful inflammatory cascades — is fundamentally different from simple immunostimulation and explains why Vilon can be beneficial in both immune deficiency and inflammatory conditions.